In 2020, Google DeepMind's AlphaFold solved a problem that had stumped biology for fifty years: predicting the three-dimensional structure of a protein from its amino acid sequence. Two years later, the team released predicted structures for virtually every known protein, more than 200 million of them, in a free and open database. The achievement earned Demis Hassabis and John Jumper the 2024 Nobel Prize in Chemistry.
But the most important chapter of the AlphaFold story is not about prizes. It is about what happens when you hand the keys to the kingdom of protein biology to researchers who are working on diseases the pharmaceutical industry ignores.
The Neglected Disease Problem
Neglected tropical diseases (NTDs) affect more than 1.6 billion people worldwide, nearly all of them in low-income countries. Chagas disease alone affects 6 to 7 million people, primarily in Latin America. Leishmaniasis kills roughly 26,000 people each year. Sleeping sickness, river blindness, and lymphatic filariasis cause immense suffering across Africa and South Asia.
These diseases receive a fraction of the R&D investment directed at conditions affecting wealthy populations. The drugs that exist are often decades old, toxic, and difficult to administer. The Drugs for Neglected Diseases initiative (DNDi), a nonprofit research organization founded in 2003, has been working to develop new treatments, but progress has been painfully slow. Understanding the molecular biology of the parasites that cause these diseases requires knowing the structures of their proteins, and experimentally determining protein structures is expensive and time-consuming.
AlphaFold Opens the Door
Before AlphaFold, determining a single protein structure through X-ray crystallography or cryo-electron microscopy could take months to years and cost hundreds of thousands of dollars. For a parasitic organism like Trypanosoma cruzi, the protozoan that causes Chagas disease, the proteome contains thousands of proteins. Solving them all experimentally was practically impossible.
AlphaFold changed the economics overnight. By making accurate structural predictions available for free, it gave researchers working on neglected diseases the same molecular-level insight that was previously available only to well-funded pharmaceutical programs. More than 3 million researchers in 190 countries have accessed the AlphaFold Protein Structure Database since its release.
The DNDi Partnership
In 2023, DeepMind and DNDi announced a formal collaboration to use AlphaFold in the search for new treatments for Chagas disease and leishmaniasis. The partnership focuses on two strategies: identifying new drug targets by analyzing the structures of essential parasite proteins, and drug repurposing, finding existing approved drugs that might bind to parasite proteins and be effective against NTDs.
Drug repurposing is particularly promising because it bypasses the most expensive and time-consuming phases of drug development. If an existing drug with a known safety profile can be shown to inhibit a key parasite protein, it can move to clinical trials much faster than a novel compound. AlphaFold makes it possible to screen existing drugs computationally against thousands of predicted protein structures, identifying candidates that would have taken years to find through traditional wet-lab screening.
Beyond Drug Discovery
The impact extends far beyond any single disease. Researchers studying antibiotic resistance are using AlphaFold to understand the mechanisms by which bacteria evade drugs. Agricultural scientists are using it to study crop pathogens and design disease-resistant plants. Environmental biologists are using it to understand the enzymes produced by plastic-eating bacteria, potentially leading to new approaches to plastic waste.
A study published in Nature in 2024 estimated that AlphaFold had already accelerated research timelines in structural biology by an average of two years per project. For fields that move slowly and are chronically underfunded, this acceleration is transformative.
AlphaFold 3 and the Future
In 2024, DeepMind released AlphaFold 3, which predicts not just individual protein structures but the interactions between proteins, DNA, RNA, and small molecules. This capability is crucial for drug discovery because drugs work by binding to specific sites on proteins. Understanding these interactions computationally can dramatically accelerate the design of new therapeutics.
The AlphaFold Server, a free online tool, allows any researcher to submit a protein sequence and receive a predicted structure within minutes. There are no paywalls, no licensing fees, and no restrictions on academic use. This open access model ensures that a researcher at a university in Lagos or Lima has the same tools as one at MIT or Oxford.
Two hundred million protein structures. Three million researchers. A partnership targeting diseases that the market ignores. AlphaFold represents something rare in the history of technology: a breakthrough that was immediately made available to those who need it most, not just those who can pay the most.
Sources: DeepMind AlphaFold Protein Structure Database; Jumper et al., "Highly accurate protein structure prediction with AlphaFold," Nature (2021); DNDi and DeepMind partnership announcement (2023); WHO neglected tropical diseases fact sheets; Abramson et al., "Accurate structure prediction of biomolecular interactions with AlphaFold 3," Nature (2024); Nobel Prize in Chemistry 2024 citation.
